|
|
|
|
|
|
|
|
|
|
interview
Monday, Jan 23, 2017
The much anticipated initial results of the Gynecologic Oncology Group (GOG) 252 trial failed to provide additional clarity for the use of intravenous (IV) versus intraperitoneal (IP) chemotherapy in patients with ovarian cancer, explains Franco M. Muggia, MD.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.